^
    Back
    Association details:
    Biomarker:BRCA2 mutation
    Cancer:Ovarian Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor) +
    adavosertib (AZD1775) (WEE1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer.

    Published date:
    05/19/2021
    Excerpt:
    A given alone and in combination with O demonstrated efficacy in pts with PARPi-resistant ovarian cancer. Although grade 3 and 4 toxicities were observed on both arms, these were generally manageable with supportive care, dose interruptions and dose reductions as needed.
    DOI:
    10.1200/JCO.2021.39.15_suppl.5505
    Trial ID:
    EFFORT